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ABSTRACT 
TAT-RasGAP317-326, a peptide corresponding to the 317-326 sequence of p120 RasGAP coupled to a cell-
permeable TAT-derived peptide, sensitizes the death response of various tumor cells to several anticancer 
treatments. We now report that this peptide is also able to increase cell adherence, prevent cell migration 
and inhibit matrix invasion. This is accompanied by marked modification of the actin cytoskeleton and 
focal adhesion redistribution. Interestingly, integrins and the small Rho GTP-binding protein, which are 
well characterized proteins modulating actin fibers, adhesion, and migration, do not appear to be required 
for the pro-adhesive properties of TAT-RasGAP317-326. On the other hand, deleted in liver cancer-1 
(DLC1), a tumor suppressor protein, the expression of which is often deregulated in cancer cells, was found 
to be required for TAT-RasGAP317-326 to promote cell adherence and inhibit migration. These results show 
that TAT-RasGAP317-326, besides its ability to favor tumor cell death, hampers cell migration and invasion. 
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INTRODUCTION 
Cancer is the second leading cause of mortality worldwide 1. A hallmark of tumor cells is their ability to 
acquire an invasive phenotype and metastasize from the primary tumor 2. Metastasis accounts for more than 
90% of cancer-related death 1,2. Metastatic dissemination begins with a cellular reprogramming that allows 
tumor cells to escape from the primary tumor, and that resumes with a long migration journey through 
tissues and in the vascular and lymphatic circulation 3,4. Metastatic cells are characterized by their ability to 
degrade the extracellular matrix at the primary site and the new colonization site, and to undergo 
intravasation and extravasation into or from the blood and/or lymph vessels 5. Although the molecular 
events during the metastatic cascade are now relatively well understood, there are not yet tools to 
effectively inhibit critical steps of the metastatic cascade, and eventually metastasis formation 6.  
A hallmark of metastatic progression and invasiveness is increased cell motility 7,8. Cell migration is a 
complex multistep and spatiotemporally organized process. It involves the integration of signals that define 
cell polarity, dynamic remodeling of cytoskeleton and focal adhesion (FA) structures as well as the 
regulation of the adhesive interaction with the extracellular environment 8. FAs are structures that link the 
exterior of the cell to the cytoskeleton through integrin transmembrane proteins. On one hand, FAs allow 
the cells to anchor on its extracellular matrix and, on the other hand, they modulate various signaling event 
involved in cell migration 9. Small GTPases of the Rho family, in particular RhoA, Rac1 and Cdc42, are 
typically triggered by integrin engagement and finely coordinate cell migration at all levels 10. As an 
example, in addition to their central function on actin dynamics regulation, Rac1 and RhoA trigger FA 
formation and maturation, respectively 11. Any impairment in these steps can result in an inefficient 
motility and therefore can compromise metastatic progression. From a therapeutic point of view, inhibiting 
cell migration is a logical approach for the development of anti-metastatic drugs since it is an early event in 
metastatic progression. 
Dysregulation of pathways regulating actin cytoskeleton dynamics and cell migration is often required for 
cancer cell to attain their full oncogenic potential 7. This can be so crucial for tumor development that some 
proteins modulating these pathways are in fact tumor suppressors, such as neurofibromatosis type-2 (NF2) 
12 and adenomatous polyposis coli (APC) 13. One other such tumor suppressor is deleted in liver cancer-1 
(DLC1), a RhoGAP protein acting on Rho and Cdc42 (ref. 14). DLC1 is mutated almost as often as p53 
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suggesting that it is a major player during cancer progression 15. Its reintroduction in DLC1-negative cancer 
cells was reported to inhibit their tumorigenicity and invasive behavior in a Rho-dependent and Rho-
independent manner 16. 
The Rasa1 gene product p120 RasGAP (from now on referred to as RasGAP) is a negative modulator of 
the Ras small GTPase. RasGAP can also interact with a large number of other proteins via proline-rich, Src 
homology, pleckstrin homology, and C2 domains 17. We previously reported that full cleavage of RasGAP 
by caspase-3 leads to the generation of fragment N2 (RasGAP158-455) that efficiently and specifically 
sensitizes cancer cells to a panel of anticancer therapy-induced cell death 18. The shortest region responsible 
for this effect resides in a 10-amino acid sequence (RasGAP317-326) within the SH3 domain 19. TAT-
RasGAP317-326 corresponds to this sequence hooked to a cell-permeable TAT-derived peptide and 
synthesized with D-amino acids. TAT-RasGAP317-326 sensitizes a variety of tumor cells to genotoxin- and 
photodynamic therapy-induced death, both in vitro and in vivo 19,20,21,22. Importantly, it does not affect 
normal cells 19,21. In the present report, we show that TAT-RasGAP317-326 increases cell adhesiveness and 
inhibits cell migration and invasion in a DLC1-dependent manner. 
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RESULTS 
 
TAT-RasGAP317-326 increases cell adhesiveness 
By serendipity, we discovered that TAT-RasGAP317-326 has a dramatic effect on cell adhesion to their 
substratum. Incubation of the U2OS human osteosarcoma cell line with TAT-RasGAP317-326, but not with 
the TAT cell-permeable sequence alone, rendered it resistant to cell detachment by trypsin/EDTA in a 
time-dependent manner (Figure 1A). Three hours after incubation with the RasGAP-derived peptide, 
approximately 50% of the cells became resistant to detachment. The percentage of non-detachable cells 
increased to 90% after 8 hours of treatment. The TAT-RasGAP317-326-induced resistance to trypsin/EDTA 
was also observed in seven other cancer and non-cancer cell lines (Figure 1B). This phenotype was found 
to be reversible 4 to 6 hours following removal of the peptide (Figure 1C). TAT-RasGAP317-326 rendered 
U2OS cells resistant not only to trypsin-mediated detachment but also to EDTA-mediated detachment 
(Figure 1D). This indicates that the mechanism allowing TAT-RasGAP317-326 to block cell detachment is 
not due to a potential inhibitory activity on trypsin. An adhesion assay was further performed to evaluate 
the effect of TAT-RasGAP317-326 on adhesion speed (Figure 1E and Supplementary Figure S1A). It 
revealed that the RasGAP-peptide was not only negatively impinging on detachment but that it also 
significantly increased the cell adhesion rate. While the TAT peptide alone induced a statistically 
significant higher adhesion speed over untreated cells, TAT-RasGAP317-326 stimulated an even faster cell 
adhesion rate. Of note, this adhesion was already detectable 30 minutes after the addition of the peptide but 
at this time point the cells have not acquired yet their ability to resist trypsin-mediated detachment (see 
Supplementary Figure S1B). TAT-RasGAP317-326 treated cells displayed a spread phenotype in comparison 
with TAT and untreated cells (Supplementary Figure S1C). The increase in cell adhesion was confirmed 
using a flow-mediated detachment assay. Untreated and TAT-treated HeLa cells were detachable by a 
strong (400 µl/s) and by a weaker (120 µl/s) flow. In contrast, while TAT-RasGAP317-326-treated cells were 
detachable by the strong flow, they remained adherent in the presence of the 120 µl/s flow (Figure 2). 
These results indicate TAT-RasGAP317-326 progressively increases cell adhesiveness and this is likely to be 
the cause of their resistance to cell detachment. 
 
 6 
TAT-RasGAP317-326 acts from within the cell 
To start defining the mechanisms by which TAT-RasGAP317-326 affects cell adhesion, we assessed the 
possibility that TAT-RasGAP317-326 acts from the outside of the cells to induce its effect on cell adhesion. 
The RasGAP317-326 peptide without the TAT cell-permeable sequence, which is therefore unable to 
efficiently penetrate cells, was unable to confer resistance to detachment (Supplementary Figure S2A) and 
to increase adhesion rate (Supplementary Figure S2B). Similar results were obtained by using another cell-
permeable sequence, R9, a peptide composed of 9 arginine residues (Supplementary Figure S2A), 
indicating that the nature of the cell-permeable moiety attached to the RasGAP317-326 sequence does not 
contribute to its activity on cell adhesion. Additionally, transfection of 293T cells with a plasmid encoding 
the RasGAP317-326 sequence rendered cells resistant to trypsin-mediated detachment (Supplementary Figure 
S2C), demonstrating that cells can increase their adherence if they synthesize their own RasGAP317-326 
peptide. Interestingly, transfection of a plasmid encoding fragment N2 (RasGAP158-455), the parental 
RasGAP-derived fragment generated by caspase-3 in apoptotic cells 18,23, also rendered cells resistant to 
detachment (Supplementary Figure S2C). This indicates that the peptide can be part of a larger polypeptide 
and still exerts its detachment resistance activity. These data provide new insights of a potential 
physiological function of fragment N2 that is generated upon high caspase-3 activity 18. Taken together, 
these results suggest that TAT-RasGAP317-326 triggers intracellular signaling pathways regulating cell 
adhesion. 
 
TAT-RasGAP317-326 mediates increased cell adherence through post-translational effects 
Next, the requirement of transcription and translation for the capacity of TAT-RasGAP317-326 to increase 
cell adhesion was evaluated. U2OS cells were treated with actinomycin D, to block transcription, or with 
cycloheximide, to block translation, and were then subjected to a trypsin-mediated detachment assay 
(Supplementary Figure S3A). These drugs efficiently inhibited transcription and translation as assessed by 
the disappearance of the short-lived c-Myc protein (Supplementary Figure S3A). In these conditions, TAT-
RasGAP317-326 was still able to increase adherence, indicating that the peptide acts post-translationally. The 
involvement of the proteasome was then tested. As shown in Supplementary Figure S3B (upper graph), the 
MG-132 proteasome inhibitor did not affect the capacity of TAT-RasGAP317-326-to prevent cell detachment 
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despite being able to inhibit cycloheximide-induced c-Myc degradation (Supplementary Figure S3B; lower 
blot). The observation that staurosporine, a compound able to inhibit ~ 90% of all kinases 24, did not affect 
TAT-RasGAP317-326-induced increased adhesiveness (Supplementary Figure S3C), indicates that most 
kinases are not mediating the effect of the RasGAP-derived peptide. The RasGAP SH3 domain that harbors 
the RasGAP317-326 sequence has the potential to dimerize 25 raising the possibility that TAT-RasGAP317-326 
interacts with RasGAP or RasGAP-derived fragments and that such interaction is required for the peptide 
to render cells resistant to detachment. However, RasGAP knock-out mouse embryonic fibroblasts (MEFs) 
became resistant to trypsin-mediated detachment when incubated with TAT-RasGAP317-326 (Supplementary 
Figure S3D). Therefore, the RasGAP-derived peptide does not require the endogenous wild-type molecule 
(i.e. RasGAP) to mediate its cellular effects on adhesion. 
 
Integrins and CD44 adhesion receptors are not required for TAT-RasGAP317-326-mediated increased 
cell adhesiveness 
We investigated whether TAT-RasGAP317-326 requires integrin functions. Integrins are heterodimers 
composed of one α and one β subunit. There are 18 different known α and β subunits that can combine to 
form 24 different heterodimers 9. About 70% (16 out of 24) of these integrin dimers are made of either the 
αV- or the β1-integrins (Supplementary Figure S4A). The fact that a melanoma cell line deficient in αV-
integrin expression 26 was rendered more adherent by TAT-RasGAP317-326 (Supplementary Figure S4B) 
together with the observation that β1 integrin silencing in HeLa cells did not prevent TAT-RasGAP317-326 
from triggering adherence (Supplementary Figure S4C) suggest however that these widespread integrins do 
not individually mediate the pro-adhesive phenotype induced by TAT-RasGAP317-326. It is unlikely that 
other integrins are targeted by the RasGAP peptide to mediate its effects on adhesion for the following 
reasons: (i) β2-, β3-, β4-, β7-integrins are expressed at very low levels or are not detected in U2OS cells 
(Supplementary Figure S4D) 27, which are cells that are responsive to TAT-RasGAP317-326. (ii) β2- and β7-
integrin expression is usually restricted to immune cells 28. We also tested the involvement of the CD44 
glycoprotein, a focal adhesion-independent adhesion receptor that can also interact with ECM 29. However, 
upon CD44 silencing in HeLa cells, TAT-RasGAP317-326 could still increase adhesion (Supplementary 
Figure S4E). Consistent with our results on integrins are the data showing that TAT-RasGAP317-326-
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mediated adhesion does not occur through a specific ECM since cell adhesion to collagen, fibronectin and 
laminin was increased by the RasGAP peptide (Supplementary Figure S4F). Altogether the results indicate 
that, CD44, β1-integrin and αv-integrin are individually dispensable for the adhesion-activating effect of 
TAT-RasGAP317-326. 
 
TAT-RasGAP317-326 remodels focal adhesions and induces actin depolymerization 
FAs are protein complexes through which the cytoskeleton is connected to the extracellular matrix and as 
such could be modulated by TAT-RasGAP317-326 to increase cell adhesion. Focal adhesion kinase (FAK), 
when recruited to activated integrins, acts as a key protein during FA formation and turnover. For example, 
it regulates the dynamic of actin fibers by favoring actin polymerization through phosphorylation of N-
WASP, actin contraction via activation of p190 RhoGEF, and actin fiber fluidity by phosphorylating α-
actinin and inhibiting its actin cross-linking capacity 30. Even though FAK-null cells are still able to form 
FAs, FAK recruitment to integrins remains a typical feature of FA formation and subsequent attachment to 
the actin cytoskeleton 30,31. To assess FA modulation and actin polymerization upon TAT-RasGAP317-326 
treatment, U2OS cells were labeled with antibodies specific for FAK, phospho-Tyr397-FAK or stained for 
filamentous actin (F-actin). A marked increase in cortical actin fibers forming peripheral concentric arc-like 
structures (Figure 3A; white arrows) was induced by the RasGAP-derived peptide, while stress fibers 
almost completely disappeared (Figure 3A; yellow arrows). Unexpectedly, the overall number of FAs 
decreased and there was a redistribution of FAs to the cell periphery. In addition TAT-RasGAP317-326 
treatment resulted in significant dephosphorylation of FAK at tyrosine 397, which indicates a reduction in 
FA turnover 32. Expression levels of the focal adhesion-associated FAK and vinculin proteins, or the 
cytoskeletal β-actin and α-tubulin, were not affected by the RasGAP-derived peptide (Figure 3B). The α-
tubulin network was also not affected by TAT-RasGAP317-326 (data not shown). Figure 3C shows that, 
using FAK knock-out MEFs, the absence of FAK did not prevent TAT-RasGAP317-326 to increase 
adherence, excluding FAK as being the target of the RasGAP-derived peptide. 
Because TAT-RasGAP317-326-treated cells exhibited a loss of stress fibers, the effect of the peptide on actin 
fiber dynamics was investigated by measuring the ratio between polymerized F-actin and monomeric G-
actin. Figure 4A shows that the F-/G-actin ratio was significantly decreased upon TAT-RasGAP317-326 
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treatment to values similar as those obtained when known actin inhibitors (latrunculin A and cytochalasin 
D) were used. Interestingly, like TAT-RasGAP317-326, both latrunculin A and cytochalasin D increased cell 
adhesion while jasplakinolide, an actin polymerization inducer, did not (Figure 4B). This suggests that actin 
depolymerization is involved in TAT-RasGAP317-326-mediated cell adhesion increase. An in vitro pyrene-
actin-based polymerization assay revealed however that RasGAP317-326 alone does not slow down actin 
polymerization (Figure 4C), indicating that TAT-RasGAP317-326-mediated actin depolymerization in cells is 
indirect. 
 
TAT-RasGAP317-326 does not require the Rho/ROCK axis to increase cell adhesiveness 
As the SH3 domain of RasGAP has been shown to remodel the actin cytoskeleton in a Rho-dependent 
manner 33, we investigated whether the activity of Rho could be modulated by the RasGAP-derived 
peptide. The level of the active GTP-bound RhoA, the main Rho family member, was assessed by 
performing a pull-down assay using the Rho-binding domain (RBD) of the Rhotekin protein that 
specifically binds to GTP-RhoA 34. TAT-RasGAP317-326-pretreated cells exhibited significantly higher peak 
of Rho activation after 1 minute of serum exposure (Figure 5A). These results show that, albeit only 
transiently, TAT-RasGAP317-326 modulates Rho activation. RasGAP and p190RhoGAP have been 
previously reported to form a complex, the biological relevance of which is thought to coordinate Ras and 
Rho-mediated signaling pathways 35. The possibility that TAT-RasGAP317-326 disrupts this complex was 
evaluated. Supplementary Figure S5 shows that the RasGAP-RhoGAP interaction was not modulated by 
the RasGAP peptide, suggesting that the increase in RhoA activity by TAT-RasGAP317-326 was not 
modulated at this level. This result is also consistent with the fact that the RasGAP-derived peptide does 
not require full-length RasGAP to mediate its effects (see Supplementary Figure S3D). 
To further understand if the TAT-RasGAP317-326-mediated transient RhoA activation was needed for the 
increase in cell adherence, a trypsin-mediated detachment assay was performed in the absence or in the 
presence of the Botulinum C3 exoenzyme Rho inhibitor or Y-27632, an inhibitor of ROCK, an effector of 
Rho. Treatment with both drugs did not prevent TAT-RasGAP317-326 from increasing adherence, indicating 
that TAT-RasGAP317-326 does not mediate adhesion increase through activation of the Rho-ROCK pathway 
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(Figure 5B). TAT-RasGAP317-326 also prevented cell shrinking/rounding induced by the C3 exoenzyme 
(Figure 5C), a possible consequence of its capacity to increase adhesiveness. 
 
 
TAT-RasGAP317-326 impairs cell migration and invasion 
It has been reported that a strong adhesion of cells to their substratum correlates with poor migration 36. 
These observations raise the possibility that TAT-RasGAP317-326 affects cell migration. Scratch wound 
healing assays were used to evaluate this assumption. Four different cancer and non-cancer cell lines 
(U2OS, HCT116, HeLa and HaCaT) were wounded and simultaneously treated or not with the peptides. A 
48 hour period of time was sufficient for untreated and TAT-only treated cells to fill the wounds entirely, 
whereas TAT-RasGAP317-326-treated cells exhibited highly impaired motility (Figure 6A; time-lapse movie 
in supplementary material). This observation was further confirmed using a transwell Boyden chamber 
migration assay in which TAT-RasGAP317-326 recapitulated the inhibition on cell migration (Figure 6B). 
Because RasGAP modulates cell proliferation through Ras, we assessed if TAT-RasGAP317-326 affects cell 
proliferation to rule out the possibility that impaired migration was a consequence of decreased 
proliferation. However, the peptide did not impair proliferation of adherent cells (Supplementary Figure 
S6A) or cells in suspension (Supplementary Figure S6B). These results were confirmed by testing the 
ability of U2OS cells to incorporate radioactive thymidine in the presence of TAT-RasGAP317-326 
(Supplementary Figure S6C). As migration is a hallmark of invasiveness, we tested whether TAT-
RasGAP317-326 could hamper cell invasion. Using a transwell Boyden chamber, it was found that TAT-
RasGAP317-326 also prevented invasion of MDA-MB-231 cells into basement membrane matrix (Figure 
6C).  
  
DLC1 is required for TAT-RasGAP317-326-mediated migration inhibition 
Several RasGAP binding partners have been identified in the past 17. Among them, DLC1, a RhoGAP with 
tumor and metastasis suppressor activities, binds the SH3 domain of RasGAP via its GAP domain 14,37. The 
reported consequence of this binding is an inhibition of the DLC1 RhoGAP activity and impairment of its 
oncosupppressive activity. Fragment N2, the RasGAP317-326-containing polypeptide that is physiologically 
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generated by high levels of caspase-3 23 and that increases cell adhesion (Supplementary Figure S2C) was 
also able to interact with DLC1 (Figure 7A). However, an alanine substitution of tryptophan 317, an 
evolutionary conserved residue within the RasGAP317-326 sequence, abrogated the ability of fragment N2 to 
bind to DLC1 (Figure 7A). A TAT-RasGAP317-326 peptide version bearing the W317A mutation failed to 
increase cell adherence (Figure 7B). These results indicate that the interaction of tryptophan 317 with 
DLC1 is essential for TAT-RasGAP317-326-mediated effects on cell adhesiveness. 
The involvement of DLC1 in the pro-adhesion and anti-migratory functions of TAT-RasGAP317-326 was 
assessed in DLC1 knock-out MEFs. In contrast to wild-type MEFs, DLC1-null MEFs were efficiently 
detached by trypsin despite the presence of TAT-RasGAP317-326, (Figure 7C) Moreover, TAT-RasGAP317-
326 did not, or only minimally, hamper migration of DLC1-null cells, in contrast again to wild-type MEFs 
that were unable to migrate into wounds in the presence of the peptide (Figure 7D). To exclude the 
possibility that the inability of the DLC1 knock-out MEFs to respond to TAT-RasGAP317-326 was caused by 
something else than the absence of DLC1, the DLC1-null cells were transfected with a DLC1-encoding 
plasmid together with a GFP-encoding plasmid to label and track the transfected cells. Figure 7E shows the 
transfected cells, in contrast to the non-transfected ones, were markedly impaired in the ability to migrate 
into wounds in the presence of TAT-RasGAP317-326. Altogether these experiments demonstrate that the 
RasGAP-derived peptide requires DLC1 to exert its pro-adhesion and anti-migratory activities. 
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DISCUSSION 
Blocking invasion is a prime strategy to inhibit the initial steps of the metastatic dissemination. In this 
study, we found that TAT-RasGAP317-326, previously shown to sensitize cancer cells to various anticancer 
treatments 19,20,21, potently inhibits cell migration and invasion by targeting the DLC1 tumor suppressor. 
Earlier reports have indicated that RasGAP can control cell migration. RasGAP knock-out MEFs exhibit 
reduced migration, while RasGAP silencing in breast cancer cells enhances their motility 38,39. These 
conflicting results could be a consequence of the different cellular systems investigated. Another possibility 
is that the dosage of RasGAP reduction influences the resulting effect on migration. It can be envisioned 
that RasGAP regulates both positively and negatively cell migration, possibly in response to different 
stimuli, but that the negative regulation requires high level of expression of the protein. In this case, 
reduction of RasGAP levels could favor cell migration. The observation that overexpression of RasGAP 
fragments correlates with decreased adherence 40 is consistent with this notion. In contrast, complete 
absence of RasGAP expression, as is the case in knock-out cells, would remove any positive effect of 
RasGAP on cell migration. However, the ability of TAT-RasGAP317-326 to inhibit cell migration does not 
involve a modulation of the full-length RasGAP protein as the peptide also blocks cell migration in 
RasGAP knock-out cells (Supplementary Figure S3). It is therefore likely that if full-length RasGAP and 
TAT-RasGAP317-326 use the same pathway to regulate cell adhesion, it is a consequence of targeting the 
same molecules and not the result of the peptide modulating the activity of the parental RasGAP protein.  
The SH3 domain of RasGAP can reorganize actin cytoskeleton in a Rho-dependent manner 33,38, 
presumably via the recruitment of p190RhoGAP 35,38. TAT-RasGAP317-326 can also favor Rho activation, at 
least transiently (Figure 5) but this apparently is not required for its capacity to increase cell adherence as 
inhibition of Rho or the Rho effector ROCK does not affect TAT-RasGAP317-326-mediated cell 
adhesiveness increase. 
Although αV- and β1-integrins were not individually required, TAT-RasGAP317-326 may nevertheless exert 
its effects through FA modulation. Rac-induced formation of nascent FAs can generate huge adhesive 
forces 11, raising the hypothesis that the RasGAP-derived peptide prevents FA maturation, therefore 
retaining FAs in their hyper-adherent state. Consistent with this hypothesis are the observations that TAT-
RasGAP317-326 induced FAK dephosphorylation and relocation of FAs to the cell periphery (Figure 3), 
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which is typical of FA turnover inhibition 11. The involvement of other adhesion receptors in TAT-
RasGAP317-326-mediated adherence, such as syndecans and cell adhesion molecules (CAMs) remains to be 
investigated. 
How can DLC1-dependent signaling increase adherence? The fact that DLC1 is located at FAs 41, where it 
binds tensin, talin and FAK 42, is certainly appropriate for a potential effect on adhesion and cell migration. 
DLC1 has indeed been shown to inhibit migration, both in Rho-dependent and Rho-independent ways 14. 
However, as mentioned above, the peptide seems to exert its effects even when Rho is inhibited indicating 
that the peptide triggers a Rho-independent DLC1-mediated signaling. Such signaling could involve the 
PLCδ1 phospholipase. DLC1 binds to and positively regulates PLCδ1, which results in PIP2 hydrolysis 43. 
PIP2 activates actin polymerization through various mechanisms [reviewed in 43] and its hydrolysis leads to 
actin depolymerization, a response indeed induced by TAT-RasGAP317-326 (Figure 4). An attractive 
possibility is that TAT-RasGAP317-326 by interacting with DLC-1 prevents the binding of the latter to 
PLCδ1 thereby decreasing PLCδ1 hydrolyzing activity and leading to actin depolymerization and 
inhibition of migration. This would also induce peripheral FA redistribution 32, a phenotype that is seen in 
TAT-RasGAP317-326-treated cells (Figure 3). The fact that displacing DLC1 from FAs, through abrogation 
of FAK and tensin binding, does not affect DLC1 RhoGAP activity 42 is consistent with our observation 
that Rho activity is not modulated by TAT-RasGAP317-326 (Figure 5). 
DLC1 may not be the only target of the RasGAP-derived peptide as some residual attachment was 
observed in TAT-RasGAP317-326-treated DLC1-null MEFs (Figure 7). For example, proteins sharing 
redundancy with DLC1, such as DLC2 and DLC3 may partially compensate for the lack of DLC1. The 
involvement of such proteins in TAT-RasGAP317-326 functions remains to be investigated.  
The present study identifies TAT-RasGAP3217-326 as an activator of cell adhesion and an inhibitor of cell 
migration and invasion. Earlier work has shown that this RasGAP-derived peptide increases the death of 
tumor cells induced by various anticancer treatments 19,20,21. Therefore TAT-RasGAP3217-326 could exert two 
beneficial effects as an anticancer agent, first by increasing the sensitivity of tumor cells to anticancer drugs 
and second by reducing the invasive potential of tumor cells. 
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MATERIAL AND METHODS 
 
Cell lines, cell culture and transfection 
All cell lines were cultured at 37°C and in 5% CO2. U2OS, 4T1, HCT116, SAOS, 3T3, RasGAP-null, 
FAK-null and DLC1-null mouse embryonic fibroblasts (MEFs), M21 (αV-integrin null), M21L (αV-
integrin positive), MDA-MB-231-Luc and 293T cells were maintained in Dulbecco's modified Eagle 
Medium (DMEM) (Gibco; Paisley; UK) supplemented with 10% fetal bovine serum (FBS) (Gibco). HeLa 
and Jurkat cells were maintained in RPMI 1640 (Gibco) supplemented with 10% FBS. HaCaT cells were 
maintained in keratinocyte medium (Invitrogen; Carlsbad; CA; USA). The 293T cells were transfected 
using the calcium-phosphate method 19,44. MEFs were transfected using the LipofectamineTM 2000 reagent 
(Invitrogen) according to the manufacturer’s instructions. 
 
Antibodies 
The antibodies used were obtained from the following sources (their dilution and specific buffer are 
described in the supplementary methods): anti-c-Myc, anti-FAK, anti-phospho-Tyr397-FAK, and anti-RhoA 
(Cell Signaling; Danvers; MA; USA), anti-vinculin (Sigma-Aldrich; St-Louis; MO; USA), anti-β-actin 
(Chemicon; Billerica; MA; USA), anti-α-tubulin (Serotec; Raleigh; NC; USA), anti-RasGAP (Enzo life 
sciences; Farmingdale, NY; USA), anti-CD44 (Abcam; UK), anti-β1-integrin (BD Pharmingen; San Jose; 
CA; USA), anti-V5 (Invitrogen), anti-HA (Covance; Princetown; NJ; USA). The secondary antibodies 
were IRDye800-conjugated anti-mouse IgG and IRDye800-conjugated anti-rabbit IgG (Rockland; 
Gilbertsville; PA; US), AlexaFluor680-conjugated anti-mouse IgG and AlexaFluor680-conjugated anti-
rabbit IgG (Molecular Probes; UK) and donkey CyTM-anti-rabbit antibody (Jackson ImmunoResearch; 
West Grove; PA; USA; for immunocytochemistry). 
 
Peptide synthesis and treatment, and plasmids 
All peptides are described and were synthesized as previously reported 19. The R9 and R9-RasGAP317-326 
peptides were kind gifts from Dr. Christoph Kündig (MedDiscovery, Switzerland). Plasmid description is 
detailed in the supplementary methods. 
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Detachment assay 
Cells were cultured until 80% confluence and were treated as indicated in the figures. After a PBS wash, 
the non-trypsinized cells were directly colored with the Giemsa stain. The other cells were incubated with 5 
g/l trypsin, 15 mM EDTA solution or with trypsin/EDTA (5 g/l trypsin, 6.8 mM EDTA) for 5 minutes. The 
cells were then washed once with PBS and colored with the Giemsa stain. Four pictures per plate were 
taken using a Zeiss Axioplan 2 microscope equipped with a 10 X objective. The number of adherent cells 
was then counted for each picture and expressed as the number of cells per mm2 or alternatively as the 
percentage of adherent cells over the non-trypsinized control. The flow-mediated detachment assay is 
precisely described in the supplementary methods. 
 
Adhesion assay 
U2OS cells were let adhering with the indicated compounds and for the indicated period of time. The 
medium was then aspirated and the cells were gently washed once with PBS and colored with the Giemsa 
stain. The data were collected as for detachment assays. 
 
Western blot analysis 
Cells were treated as indicated in the figures and Western blots were performed as previously described 19. 
Unless otherwise mentioned, forty µg of proteins were loaded.  
 
Wound-healing scratch assay, transwell migration and invasion assays 
Wound-healing scratch assays were performed as described earlier 45 and details are described in the 
supplementary methods. For the transwell migration assay, fifty thousand overnight starved 4T1 cells were 
seeded in the upper chamber of 24 transwell plates (Corning; NY; USA) for 2.5 hours. The cells were then 
subjected to the treatments indicated in the figures for 3 hours. DMEM medium complemented or not with 
10% FBS was then placed in the lower chamber of the transwell plates and the cells were allowed to 
migrate for 24 hours. Cells that migrated through the filters were quantified as described in the 
supplementary methods.  
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For the transwell invasion assay, overnight starved MDA-MB-231-luc cells were pre-treated for 2 hours 
with 20 µM TAT, 20 µM TAT-RasGAP317-326 or left untreated. Five thousand cells were resuspended in 
100 µl of 4 mg/ml Matrigel (BD Biosciences; San Jose; CA; USA) complemented or not with 20 µM TAT, 
20 µM TAT-RasGAP317-326, and placed in the top chamber. DMEM medium complemented or not with 
10% FBS was then placed in the bottom chamber and the cells were allowed to migrate through the filter 
for 48 hours. The crystal-violet colored invading cells were then counted for each condition and the results 
were expressed as the percentage of invading cells per transwell over the "control + serum" condition.  
 
Statistical analysis 
Unless otherwise mentioned, all experiments were performed three times and independently. The results 
were always expressed as mean +/- 95% confidence intervals. Unless otherwise mentioned, Student’s t-
tests were performed to assess significant differences and using the appropriate Microsoft Excel function. 
The Bonferroni correction was applied when more than one comparison was performed. One-way and 
repeated measurement ANOVAs were performed using the R software (version 2.11.0) and were followed 
by a Tukey test for multiple comparisons. Asterisks denote statistical significant differences (p-value < 
0.05). 
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FIGURE LEGENDS 
 
Figure 1. TAT-RasGAP317-326 induces cell adhesion.  
A. U2OS cells were treated or not for the indicated periods of time with 20 µM TAT or TAT-RasGAP317-
326 and were subjected to a trypsin-based detachment assay. Representative images of the cells remaining 
attached to the plates after trypsin treatment are shown on top of the panel. Scale bar: 100 µm. 
B. The indicated cell lines were left untreated or incubated for 8 hours with 20 µM TAT or TAT-
RasGAP317-326, and then subjected to a trypsin-based detachment assay. Values too low to be seen on the 
figure graphs are shown literally. 
C. Reversibility of the trypsin-mediated detachment induced by TAT-RasGAP317-326. U2OS cells were left 
untreated or incubated during 24 hours with 20 µM TAT or TAT-RasGAP317-326. The cells were then 
washed twice with PBS and further incubated for the indicated periods of time in fresh culture medium, 
followed by a trypsin-based detachment assay. 
D. TAT-RasGAP317-326 prevents EDTA-only- and trypsin-only-mediated cell detachment. U2OS cells were 
treated for 8 hours with 20 µM TAT, TAT-RasGAP317-326 or left untreated. The cells were then subjected to 
an EDTA- and trypsin-based detachment assay (n=4 independent experiments). Values too low to be seen 
on the figure graphs are shown literally. 
E. U2OS cells were subjected to an adhesion assay in presence of 20 µM TAT or TAT-RasGAP317-326 or 
without treatment (the statistical significance of the observed differences was assessed by one-way 
ANOVA).  
 
Figure 2. TAT-RasGAP317-326 increases anchorage strength of cells to their substratum.  
HeLa cells were plated on gelatin-coated coverslips and were treated for 16 hours with 20 µM TAT, TAT-
RasGAP317-326 or left untreated. They were then subjected to a flow-mediated detachment assay. The 
images shown are representative and display the cells after a detachment provoked by an intermediate 
strength flow (120 µl/s) or by an intense flow (400 µl/s). Scale bar: 100 µm. 
 
Figure 3. TAT-RasGAP317-326 remodels actin cytoskeleton and focal adhesions. 
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A. U2OS cells were treated 16 hours with 20 µM TAT, TAT-RasGAP317-326 or left untreated. 
Immunohistochemistry staining against FAK and its phosphorylated form on tyrosine 397 (in red) was then 
performed. The F-actin cytoskeleton was stained with fluorescent phalloidin (in green) and nuclei were 
stained with Hoechst-33342 (in blue). Yellow arrows point at stress fibers and white arrows at cortical actin 
fibers. Scale bar: 10 µm. 
B. U2OS cells were treated 16 hours with 20 µM TAT, TAT-RasGAP317-326 (TAT-P) or left untreated 
(Ctrl). The expression of the indicated proteins was assessed by Western blotting. Representative images 
and quantitations are shown (n=6 independent experiments).  
C. Wild-type MEFs or FAK-/- MEFs were treated for 8 hours with 20 µM TAT, TAT-RasGAP317-326 or left 
untreated and a trypsin-mediated detachment assay was performed. FAK expression was checked by 
immunoblotting. Values too low to be seen on the figure graphs are shown literally. 
 
Figure 4. TAT-RasGAP317-326 depolymerizes actin and actin depolymerization-inducing agents increase 
adherence. 
A. U2OS cells were treated for 16 hours with 50 nM of the actin polymerization promoter jasplakinolide 
(Jasp), with 500 nM of latrunculin A (Lat.A) and 5 µM cytochalasin D (CD), which are both actin 
depolymerization agents, together with 20 µM TAT, TAT-RasGAP317-326 (TAT-P) and left untreated (Ctrl). 
Ten µg of Triton-insoluble (F-actin containing) and Triton-soluble (G-actin containing) fractions were 
subjected to a Western blot directed against β-actin. The histogram shows the ratio between F-actin and G-
actin. 
B. U2OS cells were pre-treated for 1 hour with 50 nM jasplakinolide, 500 nM latrunculin A, 5 µM 
cytochalasin D or were left untreated. They were then stimulated or not for 16 hours with 20 µM TAT or 
TAT-RasGAP317-326. A trypsin-mediated detachment assay was finally performed. Values too low to be 
seen on the figure graphs are shown literally. 
C. An in vitro pyrene-actin polymerization assay was performed to evaluate the ability of RasGAP317-326 to 
modulate actin polymerization by itself. Five minutes after the beginning of the experiment, 20 µM 
RasGAP317-326, 2 µM jasplakinolide, 6 µM latrunculin A or 6 µM cytochalasin D were added to the actin-
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containing buffer, followed 20 minutes later with the addition of the actin polymerization buffer. The graph 
shown is representative of 5 independent experiments. 
 
Figure 5. TAT-RasGAP317-326 does not require the Rho/ROCK axis. 
A. U2OS cells were treated 16 hours with 20 µM TAT, TAT-RasGAP317-326 or left untreated and were then 
subjected to a RhoA activation assay (the statistical significance of the observed differences was assessed 
by one-way ANOVA). 
B. U2OS cells were treated with the indicated combinations of 20 µM TAT, 20 µM TAT-RasGAP317-326, 
10 µM of the Y-27632 ROCK inhibitor and 0.5 µg/ml of the exoenzyme C3 transferase for 8 hours. The 
cells were then subjected to a trypsin-mediated detachment assay (graph on the upper left of the panel). The 
two pictures on the right highlight the phenotype difference between TAT-RasGAP317-326- and Y-27632-
treated cells (scale bar: 50 µm). A RhoA activation assay was performed to control the inhibitory activity of 
the C3 transferase (blot on the lower left of the panel). Values too low to be seen on the figure graphs are 
shown literally. 
C. U2OS cells were pre-incubated 1 hour with 0.5 µg/ml exoenzyme C3 transferase or left untreated 
(Control), then treated with 20 µM TAT or TAT-RasGAP317-326 for 12 additional hours. Bright field 
pictures are shown. Scale Bar: 50 µm. 
 
Figure 6. TAT-RasGAP317-326 inhibits cell migration and invasion. 
A. The indicated cell lines were subjected to wound-healing scratch assays. After wounding, the cells were 
left untreated or incubated 24 and 48 hours with 20 µM TAT or TAT-RasGAP317-326. Wound widths at the 
indicated time are reported in the graphs (n=4 independent experiments). Scale bar: 100 µm. 
B. 4T1 cells were cultured in the upper chamber of transwell plates and allowed to migrate through the 
Transwell filters for 24 hours in the absence (control) or in the presence of 20 µM TAT or TAT-
RasGAP317-326. DMEM complemented (+) or not (-) with serum was added in the lower chamber. 
Quantitation was done as described in the methods. Three representative independent images are shown per 
condition. 
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C. MDA-MB-231 cells were allowed to invade the Matrigel matrix by following a serum gradient for 48 
hours in presence of 20 µM TAT, TAT-RasGAP317-326. A negative control without serum in the lower 
chamber was also performed. The invading cells were then counted and expressed as the percentage of 
invading cells per transwell over the "control + serum" condition. Representative images are shown. Scale 
bar: 50 µm. 
 
Figure 7. DLC1 is required for TAT-RasGAP317-326-mediated effects on adhesion and migration. 
A. HEK 293T cells were transfected with the indicated combinations of plasmids. Two milligrams of cell 
lysates were immunoprecipitated using an anti-V5 antibody. Forty µg of total lysates (T.L.) were also 
loaded. Western blotting against the HA and V5 tags was performed.  
B. U2OS cells treated or not for 8 hours with 20 µM TAT, TAT-RasGAP317-326 or TAT-RasGAP317-326 
bearing the W317A mutation were subjected to a trypsin-based detachment assay. 
C. Wild-type MEFs (WT) or DLC1-/- MEFs treated for 8 hours with 20 µM TAT, TAT-RasGAP317-326 or 
left untreated were subjected to a trypsin-based detachment assays. Values too low to be seen on the figure 
graphs are shown literally. 
D. WT or DLC1-/- MEFs were treated with 20 µM TAT, TAT-RasGAP317-326 or left untreated. The cells 
were then subjected to wound-healing scratch assays for 48 hours. Scale bar: 100 µm. 
E. DLC1-/- MEFs were co-transfected with a plasmid encoding GFP and with either a DLC1-encoding 
plasmid or with the empty pcDNA3 vector. The cells were then subjected to a 24 hour wound-healing 
scratch assays in the presence or in the absence of 20 µM TAT or TAT-RasGAP317-326. The migration was 
calculated as the number of GFP-positive cells that migrated through the initial wound made at 0 hour 
(yellow dotted lines). Scale bar: 100 µm. 
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SUPPLEMENTARY MATERIAL AND METHODS 
 
Antibodies  
The following antibodies were used for Western blotting. Their reference, dilution and specific buffer 
("milk" for 5% non-fat milk (in TBS [18 mM HCl, 130 mM NaCl, 20 mM Tris] containing 0.1% Tween 
(v/v)) or "BSA" for 5% BSA (in TBS containing 0.1% Tween)) are mentioned in parentheses. The primary 
antibodies used were anti-c-Myc (Cell Signaling; ref: 9402; 1:1000; BSA), anti-FAK (Cell Signaling; ref: 
3285; 1:1000; BSA), anti-phospho-Tyr397-FAK (Cell Signaling; ref: 3283; 1:1000; BSA), anti-vinculin 
(Sigma-Aldrich; ref: V9131; 1:1000; milk), anti-β-actin (Chemicon International Inc; ref: MAB1501; 
1:5000; milk), anti-α-tubulin (Serotec; ref: MCA77G; 1:1000; milk), anti-RasGAP directed at the SH3 
domain (Enzo life sciences; ref: ALX-210-860-R100; 1:250; milk), anti-CD44 (Abcam; ref: 41478; 1:1000; 
milk), anti-β1-integrin (BD Pharmingen; ref: 550531; 1:1000; milk), anti-V5 (Invitrogen; ref: 46-0705; 
1:2500; milk) (also used for immunoprecipitation), anti-HA (Covence; ref: MMS-101r; 1:1000; milk), anti-
RhoA (Cell Signaling; ref: 67B9; 1:1000; BSA). The secondary antibodies used were IRDye800-
conjugated anti-mouse IgG (Rockland; ref: 610-132-121; 1:5000; milk), IRDye800-conjugated anti-rabbit 
IgG (Rockland; ref: 611-132-122; 1:5000; milk), AlexaFluor 680-conjugated anti-mouse IgG (Molecular 
Probes; ref: A21058; 1:5000; milk) or AlexaFluor 680-conjugated anti-rabbit IgG (Molecular Probes; ref: 
A21109; 1:5000; milk). 
 
The following antibodies were used for immunocytochemistry. All the antibodies were diluted in DMEM 
containing 10% FBS. The primary antibodies used were anti-FAK (Cell Signaling; ref: 3285; 1:50), anti-
phospho-Tyr397-FAK (Cell Signaling; ref: 3283; 1:50). The secondary antibody used was a donkey CyTM-
anti-rabbit secondary antibody (Jackson ImmunoResearch; ref: 711-165-152; 1:500). 
 
Chemicals 
The following products were used in this study: actinomycin D (Calbiochem; ref: 114666), cycloheximide 
(Sigma-Aldrich; ref: C7698), MG-132 (Calbiochem; ref: 133407), staurosporin (Sigma Aldrich; ref: 200-
664-3), latrunculin A (Adipogen; ref: AG-CN2-0027), jasplakinolide (Adipogen; ref: AG-CN2-0037), 
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cytochalasin D (Applichem; ref: A7641), Y-27632 (Alexis; ref: 270-333-M001), exoenzyme C3 transferase 
(Cytoskeleton; ref: CT04), mimosine (Sigma-Aldrich; ref: 500-44-7), Hoechst-33342 (Molecular Probes; 
ref: H1399) and AlexaFluor 488 phalloidin (Invitrogen; ref: A12379). 
 
Plasmid description 
The extension .dn3 and .prc indicate that the backbone plasmids are pcDNA3 (#1) and pRc/CMV from 
Invitrogen. The pEGFP-C1 (#6) plasmid encodes the green fluorescent protein and is from Clonetech. V5-
hRasGAP[3-1931].dn3 (#686) encodes a V5-tagged version of human RasGAP that lacks its first two 
methionine residues (to prevent potential internal translation events) 1. HA-rRhoGAP.prc (#196) encodes 
the HA-tagged form of rat p190RhoGAP 1. HA-hRasGAP[158-455].dn3 (#145) previously called HA-
N2.dn3 2, encodes the HA-tagged form of fragment N2. The STag-HA-hRasGAP[158-455].dn3 (#644) 
plasmid encodes the Stag- and HA-tagged form of fragment N2. The STag was generated by PCR using 
oligonucleotide #678 [TAAGCAG (Feeder) AAGCTT (HindIII site) CTCGAG (XhoI site) 
CCACCATGGCG (including a start codon and alanine codon; the last nucleotide of the XhoI recognition 
site provides the G at the -6 Kozak position) AAA GAA ACC GCT GCT GCT AAA TTC GAA CGC 
CAG CAC ATG GAC AGC (STag) GGC TAC CCG TAC GAC GTG CCG (First 21 base pairs of 
fragment N2 (without the ATG)] and oligonucleotide #679 [GCA TTT AGG TGA CAC TAT AG: 
nucleotides 1018-999 of pcDNA3 (#1)]. The resulting 1057 base pair PCR fragment was cut with HindIII 
and subcloned into HA-hRasGAP[158-455].dn3 (#145) opened with the same enzyme. The STag-HA-
hRasGAP[158-455](W317A).dn3 (#793) plasmid encodes a Stag- and HA-tagged form of fragment N2 
bearing a mutation of tryptophan 317 into an alanine residue (W317A). The template vector used for 
starting the mutagenesis is the Stag-HA-hRasGAP[158-455].dn3 plasmid (#644). Mutagenesis was 
performed using the mega-primer procedure 3 as follows. (i) The W317A mutation was generated by PCR 
amplification of Stag-HA-hRasGAP[158-455].dn3 (#644) using oligonucleotide #978 [human RasGAP 
nucleotides 1052 to 1097 (NCBI entry M23379) except for nucleotides (underlined) that create a W317A 
mutation and a silent mutation generating a Bsu36I restriction site: GAA TTA GAA GAT GGA GCG 
(W317A) ATG TGG GTT ACA AAC C (N1-N2 of Bsu36I) TA AGG (N7 of Bsu36I) ACAGATG] and 
oligonucleotide #62 [TACCTAGCATGAACAGATTG (random sequence) AGGGGCAAACAACAGATG 
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(pcDNA3 nucleotides 1080-1063)]. (ii) The PCR product obtained in (i) was purified and elongated on the 
Stag-HA-hRasGAP[158-455].dn3 (#644) template. (iii) The PCR reaction was resumed after the addition 
of oligonucleotide #28 [TAATACGACTCACTATAGGGAGA (pcDNA3 sequence 863-885)] and 
oligonucleotide #70 [TACCTAGCATGAACAGATTG (same random sequence as in nucleotide #62)]. The 
PCR in (iii) was digested with BsiWI and NotI and ligated into plasmid STag-HA-hRasGAP[158-455].dn3 
(#644) digested with the same enzymes. The HA-hRasGAP[317-326].dn3 (#672) plasmid encodes the 
HA-tagged version of the RasGAP 317-326 sequence. The insert was created by annealing of 
oligonucleotide #736 [AATTC (cleaved EcoRI 5’ end) GCCCC (Kozak) ATG GGC TAC CCG TAC GAC 
GTG CCG GAC TAC GCT TCT (HA tag) TGG ATG TGG GTT ACA AAT TTA AGA ACA GAT 
(RasGAP317-326) TAG (Stop) G (cleaved BamHI 3’ end)] and oligonucleotide #737 [GATCC (cleaved 
BamHI 5’ end) CTA (stop) ATC TGT TCT TAA ATT TGT AAC CCA CAT CCA (RasGAP326-317) AGA 
AGC GTA GTC CGG CAC GTC GTA CGG GTA GCC CAT (HA Tag) GGGGC (Kozak) G (cleaved 
EcoRI 3’ end)]. The annealed oligonucleotides were inserted into pcDNA3 opened with BamHI and EcoRI. 
The mDLC1[1-1092].pSK plasmid (#789) encodes the Mus musculus DLC1 (deleted in liver cancer-1) 
transcript variant 2 (NM_015802.3), a gift from Dr. Nicholas C. Popescu (National Cancer Institute, 
Bethesda, US). This plasmid was obtained by subcloning the 3.3 kb cDNA of mouse DLC1 into a the 
pBluescript SK(+) vector using the Not and Xho1 restriction enzymes. The mDLC1[1-1092].dn3 (#790) 
plasmid encodes the same version of DLC1 under the control of a CMV promoter. The 3.3 kb fragment 
DLC1 cDNA fragment was excised from plasmid mDLC1[1-1092].pSK (#789) using NotI and XhoI and 
subcloned into pcDNA3 (#1) opened with the same enzymes. The V5-mDLC1[1-1092].dn3 (#791) 
plasmid encodes the V5-tagged version of the DLC1 construct. It was generated by PCR amplification of 
mDLC1[1-1092].dn3 plasmid (#790) with oligonucleotide #975 [GGTGGT (feeder) GCGGCCGC (NotI 
site) GCCACC (Kozak) ATG (start) GGA AAA CCA ATA CCA AAT CCA CTA CTA GGC CTA GAC 
AGT ACA (V5-tag) ATC CTA ACA CAA ATT GAA GCC AAG (nucleotides 376-399 of mouse DLC1 
transcript variant 2; NM_015802.3)] and oligonucleotide #976 [TTGTTACAGGTGCTGAGGCT 
(nucleotides 1352-1333 of mouse DLC1 transcript variant 2; NM_015802.3)]. The resulting 1013 base pair 
fragment was cut with NotI and BstEII and subcloned into mDLC1[1-1092].dn3 (#790) opened with the 
same enzymes. 
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Giemsa staining 
Cells were washed once in PBS and air-dried overnight at room temperature. The next day, they were 
incubated 10 minutes in 100% ethanol and air-dried for 1 hour at room temperature. They were then 
colored with 2 ml of a Giemsa stain solution (4 mg/ml in methanol; Sigma-Aldrich; ref: G3032) per 3.5 cm 
plates (or 10 ml for 8.4 cm plates) for 45 minutes. The Giemsa solution was then discarded and the plates 
were immersed in a 5 liter becher containing tap water for 10 minutes. The water was then replaced with 
fresh water and this procedure was repeated until the background staining has been washed away, revealing 
the stained cells. The plates were then air-dried and kept at room temperature until analysis. 
 
Flow-mediated detachment assay 
HeLa cells were seeded on 20 mm coverslips coated with 0.1% gelatin (in PBS). The cells were then 
treated with 20 µM TAT, 20 µM TAT-RasGAP317-326 for 8 hours or were left untreated. The coverslips 
were then washed in PBS and mounted in a home-made ovoid flow-chamber and the cells were subjected 
to different intensities of PBS flows. The 120 µl/s flow was reached using a perfusion hanged 2.2 m above 
the flow chamber and the 400 µl/s flow was reached by manual PBS injection using a syringe. After the 
assay, the undetached cells were colored with the Giemsa stain and pictures were taken.  
 
Immunocytochemistry 
U2OS cells were grown overnight on coverslips, and then treated as described in the figures. The 
immunocytochemistry was performed as described earlier 4. Prior to antibody incubation, the cells were 
incubated 20 minutes in PBS containing 1.65 µM Alexa Fluor 488 phalloidin (Invitrogen). Images were 
taken with a Zeiss Axioplan 2 imaging microscope and were similarly treated for their intensities and 
contrasts using Adobe Photoshop CS5. 
 
Immunoprecipitation 
Transfected 293T cells were lysed in 1% NP-40 lysis buffer. The amount of protein extract used for 
immunoprecipitation is indicated in the figures. The immunoprecipitation was performed using the 
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Dynabeeds Protein G technology according to the manufacturer’s instructions (Novex) and subjected to 
Western blotting. 
 
siRNA-mediated gene silencing 
The silencing was performed as follows: one hundred fifty thousand HeLa cells were cultured overnight in 
3.5 cm plates in DMEM complemented with 10% FBS. The day after, the siRNA (Microsynth, 
Switzerland) were transfected using Lipofectamine TM 2000 (Invitrogen, ref: 11668-019) according to the 
manufacturer's instructions. Two hundred pmol of siRNA and 4 µl of Lipofectamine were used per well. 
The cells were transfected for the indicated period of time and followed by the indicated assays. The 
silencing was performed using the following siRNAs: β1-Integrin (5’-dTdT-AAU GUA ACC AAC CGU 
AGC ATT-dTdT-3’), CD44 (5’-dTdT-UUC CAG AAU GGC UGA UCA U-dTdT-3’). 
 
Extracellular matrix coating 
Collagen was purified as previously described 5. Two hundred µl drops of PBS or of the different 
extracellular matrix components [25 µg/ml fibronectin (BD Biosciences; ref: 354008), 50 µg/ml laminin 
(Boehringer Mannhein; ref: 1243217) and 3.9 mg/ml self-purified collagen] were laid on the surface of 9.2 
cm bacteriologic Petri dishes (Sarstedt; ref: 82.1473) for 4 hours. These drops were then aspirated and the 
coated regions were washed with 200 µl PBS drops, and then aspirated again. Cells were then grown on 
these coated dished as mentioned above. 
 
Actin assays: F-actin/G-actin ratio measurement and pyrene-actin in vitro polymerization assay 
F- and G-actin were purified as previously reported 6 and the Triton-insoluble fractions (F-actin containing 
fractions) were washed once in lysis buffer and dissolved in 1% SDS buffer for 10 minutes at 96°C.  
Actin in vitro polymerization was carried out using a kit purchased from Cytoskeleton (Denver; CO; USA). 
Briefly, One hundred µl of 2.38 µM rabbit skeletal muscle pyrene-G-actin (100 µg/ml) were added per well 
of a 96-well plate (Costar; ref: 07-200-590). After 355 nm wavelength excitation, the fluorescence emitted 
at 410 nm was measured every minute for the whole duration of the experiment. Five minutes after having 
started the recording, the actin mix was treated with 20 µM RasGAP317-326, 2 µM jasplakinolide, 6 µM 
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latrunculin A or 6 µM cytochalasin D (so that the compound volume corresponds to 2 µl) and the 
measurement went on. Twenty minutes after compound incubation, ten µl actin polymerization buffer from 
the kit were added to the mix and the measuring went on until the end of the experiment. 
 
RhoA activation pull-down assay 
The cellular level of GTP-loaded RhoA was determined as previously reported 7. U2OS cells were starved 
overnight in DMEM without serum in combination with 20 µM TAT, 20 µM TAT-RasGAP317-326 or 
without treatment. The cells were then stimulated with DMEM complemented with 10% serum as indicated 
in the figures and processed as reported 7. 
 
Wound-healing scratch assay 
Confluent cells were wounded with a tip. The cells were then washed once with PBS and incubated in fresh 
medium in the conditions indicated in the figures. Pictures of the plates were taken just after wounding (0 
hour) and at the indicated times. The same five fields per wound were photographed at each time point. The 
results were either reported as wound widths measured as described earlier 8. Alternatively, the 48 hour 
wound area was subtracted from the 0 hour wound area (quantitated using ImageJ) and expressed as a 
percentage of the untreated condition. Time-lapse microscopy was performed during 48 hours by taking 
brightfield snapshots every 5 minutes. 
 
Transwell migration and invasion assay 
After migration or invasion of cells into the filters of the Transwells, the cells that did not migrate or invade 
were removed by scraping with a cotton swab. The cells remaining within the filter were fixed in 4% 
paraformaldehyde for 10 minutes, rinsed 3 times in sterile water, stained with 0.5% (w/v) crystal violet 
(Acros, ref: 548-62-9) in 25% methanol (v/v) for 10 minutes, and then rinsed again 5 times in water. The 
quantitation of the violet area was done using the Adobe Photoshop software (Creative Suite 3) as follows. 
Pictures of the filters were taken at the same magnification and with the same luminosity condition using a 
stereoscopic zoom microscope (Nikon SMZ1000) equipped with a digital camera (Nikon DS-L2). The 
surface occupied by the cells, i.e. the violet-stained surface, was measured as follows. The Adobe 
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Photoshop software (Creative Suite 3) was used to draw a circle positioned on the center of the filter in the 
image. The diameter of the circle was set to 3/4 of the diameter of the actual filter (this ensures that cells 
close the walls of the wells, which are not efficiently removed with the cotton swab, do not artefactually 
alter the results). The magic wand tool was used to select the violet area and the tolerance was adjusted for 
each picture in order to discriminate the violet area from the non-stained area. The number of pixels of the 
violet area was determined (from the histogram window in Photoshop) and converted in mm2 (the area of 
the circle corresponds to 79'868 pixels and 86.5 mm2). 
 
Cell density measurement 
A one cm2 grid was drawn on the bottom of 3.5 cm plates. Thirty thousand U2OS cells were seeded in 
those plates and cultured overnight. The cells were then treated as indicated in the figures. The number of 
cells within the one cm2 square was determined at the time of treatment initiation and on the next two 
consecutive days. Cell density was expressed as number of cells per mm2. For Jurkat cell proliferation 
measurement, one hundred thousand cells were diluted in 5 ml RPMI supplemented with 10% FBS, in 3.5 
cm plates. The cells were directly treated with 20 µM TAT, 20 µM TAT-RasGAP317-326 or left untreated 
and cell density assessed using a Neubauer counting chamber. 
  
Radioactive thymidine incorporation assay 
U20S cells were cultured and treated 16 hours with 400 µM Mimosin, 20 µM TAT, 20 µM TAT-
RasGAP317-326 or left untreated. [14C]-thymidine (0.01 µCi per well) (Perkin Elmer; ref: NEC1560110UC) 
was then added for 2.5 hours. Each well was washed four times with PBS and the cells were lysed in RIP-
A, spotted on glass microfiber filters (Whatman; ref: 10370018) and dried for 30 minutes. These filters 
were subsequently soaked into four different baths in the following order: (1) 10% TCA (trichloroacetic 
acid; Sigma; ref: 33731), (2) 5% TCA, (3) 50% ethanol + 50% ether and (4) 100% ether, and were dried 1 
hour in scintillation vials. Each filter was then solubilized and beta particle emission was measured for 10 
minutes. These emission values were normalized to the amount of proteins in the samples and further 
normalized to the non-treated control.  
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Supplementary movie. TAT-RasGAP317-326 inhibits cell migration 
This movie displays a time-lapse recording of a wound healing scratch assay. U2OS cells were treated 
as indicated in the methods with 20 µM TAT, 20 µM TAT-RasGAP317-326 or left untreated (control). 
Bright field pictures were taken every 5 minutes during 48 hours using a Zeiss LSM 710 NLO 
microscope equipped with a 10x objective. The cells were maintained at 5% CO2 and 37°C for the 
whole duration of the experiment. The movie was then generated using the Metamorph software. 
